Quantcast
Home > Quotes > VICL
VICL

Vical Incorporated Common Stock (VICL) Quote & Summary Data

$1.23
*  
unch
unch
Get VICL Alerts
*Delayed - data as of Mar. 25, 2019  -  Find a broker to begin trading VICL now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
2.3
Today's High / Low
$ 1.23 / $ 1.21
Share Volume
93,831
50 Day Avg. Daily Volume
418,350
Previous Close
$ 1.23
52 Week High / Low
$ 1.82 / $ 0.85
Market Cap
26,838,840
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.32

Intraday Chart

Shares Traded

Share Volume:
93,831
50 Day Avg. Daily Volume:
418,350

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.75

Trading Range

The current last sale of $1.23 is 44.71% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.23 $ 1.82
 Low: $ 1.21 $ 0.85

Company Description (as filed with the SEC)

Until recently, we were focused on developing our novel antifungal VL-2397, for the treatment of patients with invasive aspergillosis. VL-2397 was being evaluated in a multicenter, open label randomized Phase 2 clinical study, designed to compare the efficacy and safety of VL-2397 to standard treatment for invasive aspergillosis in acute leukemia patients and recipients of allogeneic hematopoietic cell transplant (HCT). In February 2019, we decided to discontinue the Phase 2 clinical trial of VL-2397 in order to conserve our cash resources while we pursue our strategic alternative review process. Our board of directors is conducting a review of strategic alternatives, including, but are not limited to, merger or acquisition transactions, issuing or transferring shares of our common stock, or the license, purchase or sale of specific assets, in addition to other potential actions aimed at maximizing stockholder value.  ... More ...  



Risk Grade

Where does VICL fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.23
Open Date:
Mar. 25, 2019
Close Price:
$ 1.23
Close Date:
Mar. 25, 2019


Consensus Recommendation

Analyst Info